La cadena de opciones muestra datos clave de las opciones de acciones de SpringWorks Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para SpringWorks Therapeutics..

SpringWorks Therapeutics (NASDAQ:SWTX) Bolsa, Cadena de Opciones

SPRINGWORKS THERAPEUTICS INC

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Philip Ng downgraded Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) from Buy to Hold and lowered the price target from $245 to $205. Packaging Corp of America shares closed at $188.56 on Friday. <a href="https://www.benzinga.com/quote/PKG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor downgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Sell and lowered the price target from $40 to $10. Sarepta Therapeutics shares closed at $36.18 on Friday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Nicholas Jones downgraded the rating for Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Market Outperform to Market Perform. Angi shares closed at $15.44 on Friday. <a href="https://www.benzinga.com/quote/ANGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Allen Klee downgraded Ohmyhome Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMH#NASDAQ">OMH</a>) from Buy to Hold. Ohmyhome shares closed at $1.42 on Friday. <a href="https://www.benzinga.com/quote/OMH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Rob Oliver downgraded PROS Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRO#NYSE">PRO</a>) from Outperform to Neutral and lowered the price target from $27 to $18. Pros Holdings shares closed at $15.78 on Friday. <a href="https://www.benzinga.com/quote/PRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/srpt/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="624" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16094549/image-244-1024x624.png" alt="" class="wp-image-950814" style="width:697px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16094549/image-244-1024x624.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16094549/image-244-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16094549/image-244-768x468.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16094549/image-244.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45946608/top-3-materials-stocks-that-could-blast-off-this-month-3">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

News

Downgrades

Analyst Ratings

Trading Ideas

ANGI

SRPT

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Supernus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) for $12.00 per share in cash, or an aggregate of up to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45945434/supernus-pharmaceuticals-to-acquire-sage-therapeutics-strengthening-its-neuropsychiatry-product-po" rel="noreferrer noopener">approximately $795 million</a>.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a>
<h2 class="wp-block-heading">Strategic and Financial Benefits</h2>
The acquisition significantly strengthens Supernus Pharmaceuticals&#8217; psychiatry portfolio by adding Zurzuvae (zuranolone) capsules CIV, a landmark drug that stands as the first and only oral medicine approved by the FDA for treating postpartum depression in adults.
This strategic addition is set to diversify and substantially increase Supernus Pharmaceuticals&#8217; revenue base and cash flow. The financial impact is already evident from the collaboration revenue derived from Zurzuvae&#8217;s net sales, which, representing 50% of the net revenue recorded by Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), amounted to $36.1 million for the full year 2024 and $13.8 million in the first quarter of 2025 alone.
Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.
Beyond the immediate commercial benefits, the deal also augments Supernus Pharmaceuticals&#8217; central nervous system (CNS) discovery platforms and deepens its expertise in the field.
Furthermore, the strong integration potential with Supernus Pharmaceuticals&#8217; existing infrastructure is expected to yield substantial operational efficiencies, with projected annual cost synergies of up to $200 million.
&#8220;This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. Zurzuvae aligns with our focus of acquiring novel value-enhancing and clinically differentiated medicines to treat CNS conditions,&#8221; said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
In a significant development preceding the acquisition by Supernus Pharmaceuticals, Biogen Inc. had made an unsolicited, non-binding proposal to acquire all of the outstanding shares of Sage Therapeutics that it did not already own. The offer was made on January 10, 2025, for a price of $7.22 per share.
In October 2024, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-" rel="noreferrer noopener">in postpartum depression</a>.
The company said the reorganization was intended to strengthen Sage&#8217;s balance sheet, extend its cash runway, and position the company for long-term growth potential.
The company&#8217;s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&amp;D workforce), including changes to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">the leadership team</a>.
In September 2024, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">SAGE-324 program</a>.
Price Action: SAGE stock was trading higher by 36.3% to $9.13 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44190052/johnson-johnson-stops-late-stage-depression-study-over-insufficient-efficacy" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Stops Late-Stage Depression Study Over &#8216;Insufficient Efficacy&#8217;</a></li>
</ul>
Photo Courtesy: S Prodution on Shutterstock.com

Biotech

Health Care

Movers

General

BIIB

SAGE

SUPN

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

"Bail yourself out," bestselling personal finance author <a href="https://www.benzinga.com/personal-finance/25/03/44477627/robert-kiyosaki-says-bitcoin-gold-and-silver-are-the-future-heres-why-he-avoids-etfs">Robert Kiyosaki </a>urges, predicting a 2025 crash that could eclipse the chaos of 2008.&nbsp;
The bestselling author of "Rich Dad Poor Dad" urges households to swap fiat cash for gold, silver and bitcoin, insisting that "savers are losers." His warning comes as gold breaches $3,228 an ounce and student-loan payments resume for millions of Americans, adding to growing financial anxiety.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">From LTCM To Student Loans</h2>
On May 18, Kiyosaki posted a message on<a href="https://x.com/theRealKiyosaki/status/1924170242609275368"> X</a>, recasting his oft-repeated line that the rich don't work for money. The tweet tagged economic commentator Jim Rickards and warned that every rescue since the dollar left gold in 1971 has only moved the next crisis higher up the food chain.
History is the backbone of Kiyosaki's thesis. He cites the September 1998 bailout of Long-Term Capital Management, when 14 banks <a href="https://www.federalreservehistory.org/essays/ltcm-near-failure">pumped</a> $3.6 billion into the teetering hedge fund during talks convened by the Federal Reserve Bank of New York.&nbsp;
A decade later, central banks created a multitrillion-dollar safety net for Wall Street after Lehman Brothers collapsed. If, as Rickards asks, the rescuer now needs rescuing, the size of the bill may dwarf anything seen before.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
Those fears are already showing up in asset prices. Gold pierced the $3,300 barrier on April 16, touching a record $3,317.90 per ounce as traders chased hard assets amid fresh U.S.–China tariff volleys and a sliding greenback.&nbsp;
Strategists now float $3,500 targets, arguing that central bank buying and sticky inflation leave little appetite for paper promises. The digital-asset crowd has been just as resolute. Bitcoin recently surged past $110,000 as market momentum remains strong amid broader economic uncertainty.
The household backdrop, meanwhile, looks fragile. According to <a href="https://www.ed.gov/about/news/press-release/us-department-of-education-begin-federal-student-loan-collections-other-actions-help-borrowers-get-back-repayment">Department of Education</a> data, more than 5 million borrowers have been in default for over 360 days, and 4 million are in late-stage delinquency. If trends continue, nearly 10 million—roughly 25% of the federal student‑loan portfolio—could be in default soon.
A May 13, report from the <a href="https://www.newyorkfed.org/newsevents/news/research/2025/20250513">Federal Reserve Bank of New York</a> found the share of student debt in serious delinquency has leapt to 8%, its highest since 2020. Economists warn this surge may impact borrowers' credit profiles, with lost discretionary spending in heavily delinquent regions potentially rippling through retail sales and job growth, the <a href="https://www.ft.com/content/0ae46934-ea09-4dc9-bab4-4aa945542ff4">Financial Times</a> reported.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Kiyosaki distills the lesson into three assets: physical <a href="https://www.benzinga.com/25/05/45484394/gold-hits-3500-as-larry-summers-says-u-s-market-is-on-a-path-to-crisis-like-uks-2022-meltdown">gold</a>, physical silver, and Bitcoin stored offline. In the post, he urged followers to avoid exchange-traded substitutes, arguing that ETFs carry the very counterparty risks he fears.&nbsp;
The upshot, he said, is that families can no longer rely on central banks or Congress; personal balance sheets must become the first and last lines of defense.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Bail Yourself Out,' Warns Robert Kiyosaki — Says The 2025 Crisis Could Be Worse Than 2008 And 'Savers Are Losers' In This Economy

CTLP

Trading Halt: Halt status updated at 9:45:00 AM ET: Quotation Resumption: News and Resumption Times

Tigress Financial analyst Ivan Feinseth initiates coverage on MNTN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNTN#NYSE">MNTN</a>) with a Buy rating and announces Price Target of $28.

Price Target

Initiation

MNTN

Tigress Financial Initiates Coverage On MNTN with Buy Rating, Announces Price Target of $28

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) are flexing serious silicon muscle as demand surges for <a href="https://www.benzinga.com/topic/semiconductors">custom AI ASIC chips</a> — next-gen application-specific integrated circuits designed to outpace off-the-shelf GPUs from Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
<h2 class="wp-block-heading">ASIC Arms Race: Custom Chips Are The New Gold</h2>
According to JPMorgan analyst Harlan Sur, both companies have now secured 2nm design wins for AI accelerators powering hyperscalers like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google, Meta Platform Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). 
With the total ASIC market poised to hit $30 billion in 2025 and growing at a 30% clip, Broadcom and Marvell are not just playing catch-up — they're building the racetrack.
This boom is driven by the hyperscalers' appetite for AI compute power with better performance, lower power, and reduced silicon costs. As AI models swell past 100 billion transistors per chip, these tech giants are leaning on ASIC veterans like Broadcom and Marvell to bring their custom accelerators to life &#8211; and fast.
Read Also: <a href="https://www.benzinga.com/markets/options/25/06/45893665/mrvl-stock-trade-agreement-sleeper-options-opportunity">Options Corner: Why The Latest U.S.-China Trade Agreement Makes Marvell A Sleeper Opportunity</a>
<h2 class="wp-block-heading">Broadcom Leads the Charge, Marvell Fights From Behind</h2>
Broadcom, the market leader with 55%-60% share, is already clocking in major wins: from Meta's MTIA 2nm to Google's TPU v8. JPMorgan expects Broadcom's AI revenue to hit $31 billion next fiscal year — a 60% jump. The stock, up nearly 36% in the past year, is still rated Overweight by JPMorgan, with a bullish $283.33 average price target from Citigroup, Barclays and Susquehanna.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="628" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085605/Screenshot-2025-06-16-at-6.25.27-PM.png" alt="" class="wp-image-950734" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085605/Screenshot-2025-06-16-at-6.25.27-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085605/Screenshot-2025-06-16-at-6.25.27-PM-300x232.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically too, AVGO is a buy across key longer-term averages.
Marvell, trailing with a 15% share, has momentum too. It's already ramping up production for Amazon's Tranium 2 and Google's Axion CPU and has landed design wins for 2nm next-gen chips at AWS and Microsoft. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="628" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085638/Screenshot-2025-06-16-at-6.25.40-PM.png" alt="" class="wp-image-950737" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085638/Screenshot-2025-06-16-at-6.25.40-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16085638/Screenshot-2025-06-16-at-6.25.40-PM-300x232.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Yet despite its potential, the stock tells a different story — down 41% year-to-date and trading below its 200-day average. Analyst sentiment remains bullish, with Loop Capital and China Renaissance setting targets as high as $90 and $110, respectively, but the near-term setup looks shakier.
So who wins this silicon sprint? 
Broadcom has the scale, the pipeline, and the technical tailwinds. Marvell may be a promising underdog &#8211; but right now, it's Broadcom that's doing the heavy lifting.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45790867/how-nvidias-10-ripple-effect-could-lift-adobe-salesforce-servicenow">How Nvidia&#8217;s $10 Ripple Effect Could Lift Adobe, Salesforce, ServiceNow</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

AMZN

AVGO

GOOG

GOOGL

MRVL

MSFT

NVDA

Broadcom, Marvell Ride The $30B ASIC Wave – But Only One Looks Ready For Takeoff

In the ongoing tariff negotiations, the United States is reportedly urging Vietnam to reduce its reliance on Chinese technology in the production of devices that are later exported to the U.S.
What Happened: The U.S. is pressuring Vietnam to decrease its use of Chinese technology in the production of devices that are later exported to the U.S. This move could significantly impact Vietnam&#8217;s export-oriented growth model, which is heavily reliant on the U.S. market, reported Reuters on Monday.
&#8220;That is part of the restructuring of supply chains and would in turn reduce U.S. dependency on Chinese components,&#8221; a source told Reuters.
The Trump administration has threatened Vietnam with steep tariffs &#8220;of up to 46%,&#8221; a move that could significantly restrict the country&#8217;s access to its main export market and disrupt its export-driven economy. The U.S. is also pressuring Vietnam to crack down on the transshipment of Chinese goods falsely labeled as &#8220;Made in Vietnam,&#8221; a practice that Vietnam is actively working to curb.
Vietnam, home to major manufacturing operations of tech giants like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Samsung Electronics Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), has been organizing meetings with local businesses to increase the supply of Vietnamese parts. While firms have shown readiness to collaborate, they have also cautioned that they would require time as well as technology to do so.
SEE ALSO: <a href="https://benzinga.com/markets/tech/25/06/45943342/google-microsoft-elon-musks-xai-reportedly-cut-ties-with-scale-ai-after-mark-zuckerbergs-meta-buys-s" target="_blank" rel="noreferrer noopener">Google, Microsoft, Elon Musk&#8217;s xAI Reportedly Cut Ties With Scale AI After Mark Zuckerberg&#8217;s Meta Buys Stake</a>
Why It Matters: The U.S.&#8217;s push for Vietnam to reduce its reliance on Chinese technology comes amid the ongoing trade tensions between the U.S. and China. This development also follows Chinese President Xi Jinping&#8216;s <a href="https://www.benzinga.com/25/04/44806095/as-xi-jinping-urges-vietnam-to-stand-against-unilateral-bullying-trump-labels-the-meeting-a-plan-to-screw-the-united-states-of-america">diplomatic tour</a> of Southeast Asia, where he urged countries like Vietnam to stand against &#8220;unilateral bullying&#8221; and uphold free and open trade.
Earlier in April, President Donald Trump revealed that Vietnam was interested in negotiations to <a href="https://www.benzinga.com/news/global/25/04/44650903/trump-reveals-vietnam-trade-talks-as-nike-stock-rallies-on-surprise-turnaround">reduce tariffs</a>, a move that was well received by the market. 
The current development, however, indicates a potential shift in Vietnam&#8217;s trade dynamics, as it navigates the demands of both the U.S. and China. Reuters also reported that Vietnam views the demands of the U.S. as  &#8220;tough&#8221; and &#8220;difficult.&#8221; 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/crypto/25/06/45941991/bitcoin-ethereum-consolidate-dogecoin-dips-as-iran-israel-conflict-rages-on-these-levels-will-define-direction-of-btcs-next-breakout-says-analyst" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Consolidate, Dogecoin Dips As Iran-Israel Conflict Rages On: These Levels Will Define Direction Of BTC&#8217;s Next Breakout, Says Analyst &#8211; Grayscale Bitcoin Mini Trust (BTC) Common units</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AAPL

SSNLF

US Pressures Vietnam To Cut Chinese Tech Dependency Amid Tariff Talks: Report

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $9 price target.

GOVX

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $9 Price Target

BWS Financial analyst Hamed Khorsand maintains Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) with a Buy and maintains $74 price target.

INOD

BWS Financial Maintains Buy on Innodata, Maintains $74 Price Target

Goldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $37.

ELVN

Goldman Sachs Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $37

Guggenheim analyst Vamil Divan upgrades Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) from Neutral to Buy and announces $14 price target.

Upgrades

JBIO

Guggenheim Upgrades Jade Biosciences to Buy, Announces $14 Price Target

Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are rising Monday after the company announced a new <a href="https://www.benzinga.com/pressreleases/25/06/b45942277/amazon-ads-and-roku-announce-partnership-creating-the-largest-authenticated-ctv-footprint">strategic integration with Amazon Ads</a>. 
What To Know: Roku entered into a new exclusive partnership with Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Ads, providing access for advertisers to the largest authenticated Connected TV (CTV) footprint in the U.S. exclusively through Amazon&#8217;s demand-side platform (DSP).
The deal will deliver logged-in reach to an estimated 80 million CTV households in the U.S., opening up improved performance, planning and optimization for advertisers. The companies said early tests showed the integration allows advertisers to reach up to 40% more unique viewers with the same budget, and decreases how often the same person sees the same ads by close to 30%.
&#8220;This collaboration delivers a unified, future-ready solution at an unprecedented scale, one designed to drive measurable outcomes by unlocking performance across CTV,&#8221; said Charlie Collier, president of Roku Media. 
&#8220;With nearly half of all TV streaming time in the U.S. happening on Roku, and the power and depth of Amazon in retail and beyond, together we&#8217;re uniquely positioned to prove performance and differentiate DSP offerings for our shared advertisers and marketers.&#8221;
The integration allows Amazon DSP to recognize logged-in viewers across the Roku&#8217;s operating system and devices in the U.S., resulting in more precise reach, measurable results and greater control over ad frequency.
&#8220;We&#8217;re removing the guesswork to provide advertisers with unprecedented capabilities and delivering performance in ways that simply weren&#8217;t possible before,&#8221; said Paul Kotas, senior vice president of Amazon Ads. 
ROKU Price Action: <a href="http://benzinga.com/quote/ROKU">Roku shares</a> got a significant boost from the deal, last up 9.91% at $81.78 Monday morning, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45943758/amazon-commits-13-billion-to-expand-australias-ai-data-center-infrastructure">Amazon Commits $13 Billion To Expand Australia&#8217;s AI Data Center Infrastructure</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45948410/5-stocks-in-the-spotlight-from-wall-streets-most-accurate-analysts-last-week-5">5 Stocks In The Spotlight From Wall Street&#8217;s Most Accurate Analysts Last Week</a></li>
</ul>
Image: Shutterstock.

ROKU

Roku Stock Surges On New Integration With Amazon: Details Of The Deal

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our pivotal level of 600.51. Bullish traders will aim to drive prices upward past 601.22, securing this mark as solid intraday support. If buyers maintain momentum at 601.22, we anticipate further upside toward the key resistance at 602.37. A sustained push beyond that level may trigger additional buying, targeting the next level at 603.38, with a potential daily high at 604.45.&nbsp;
On the downside, should SPY fail to maintain support at 600.51, bearish momentum could take hold, pressing prices initially toward 599.24. Sellers stepping in decisively at this juncture would open further decline to 598.04. If selling accelerates strongly, watch for a critical support test at 596.57. Intense bearish activity today could ultimately drive SPY down to our lower target at 595.14.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is presently trading around the critical juncture of 530.70. Bulls will first look to establish dominance by stabilizing above this area, building momentum toward securing 532.52 as support. Continued bullish strength above this zone would set the stage for an attempt at 533.70, and vigorous buying activity might elevate prices to the next resistance at 534.60, with the day's bullish target set at 535.30.&nbsp;
Conversely, if buyers fail to maintain control above 530.70, sellers are likely to seize the initiative, driving prices down sharply to 528.44. Persistent bearish pressure could further weaken the market, potentially testing 527.03. If that support is breached decisively, anticipate a deeper sell-off to 525.19. Extended downside momentum would then place our ultimate bearish objective at 523.91.
Apple Inc. (AAPL)
Apple shares are currently trading around our pivotal area at 197.69. Bulls will initially target a firm hold above 198.22, seeking to catalyze an upward move to 198.79. If bullish momentum continues unabated, expect the price to extend toward 199.51. A notably strong rally could ultimately carry Apple to today's bullish target at 200.53.&nbsp;
However, should Apple falter and lose support at 197.69, expect bearish momentum to quickly target a downward move toward 197.00. Continued selling pressure would then push prices further to 196.61. Breaking this level decisively could see sellers dominating further, potentially moving prices lower toward the 196.01 support. A deepening bearish scenario would ultimately test our downside target of 195.67.
Microsoft Corp. (MSFT)
Microsoft is currently hovering around our significant level at 476.18. Bulls need to consolidate strength above this mark, aiming first for 477.66, turning it into reliable intraday support. Successfully holding that level could ignite a further rally toward 478.82, with sustained bullish action pushing Microsoft toward the high bullish target for the day at 480.04.&nbsp;
If Microsoft fails to maintain 476.18 as firm support, bears could swiftly retake control, driving prices down to probe the support at 474.99. Additional selling strength below this point might push the market further toward 473.80. Extended bearish sentiment could potentially accelerate the decline toward 472.91, with our daily bearish target identified at 472.11.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading near our critical support and resistance pivot at 143.41. Bulls will look to elevate prices swiftly past 144.21, establishing this point as new support. Successful consolidation here could generate further bullish momentum, pushing toward 145.61. Persistent buying would encourage the next leg upward to 147.06, potentially reaching today's high bullish target of 148.52.&nbsp;
Conversely, if the price cannot sustain above 143.41, bearish traders will likely seize momentum, driving the market down to the next critical test at 142.35. Failure at this support could accelerate selling, sending prices lower toward 141.21. Continued bearish sentiment would then challenge support at 140.28, with sustained selling pressure potentially dragging NVIDIA down to the daily bearish target at 139.42.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading at our key pivot level of 176.23. For bulls, maintaining a firm hold above this level is essential to catalyze further upside momentum toward 177.28. Sustained bullish activity could fuel an additional push higher, ultimately targeting today's bullish objective at 179.15.&nbsp;
If Alphabet fails to maintain 176.23 as reliable support, sellers could aggressively enter the market, driving prices lower toward 175.12. Breaching that support decisively could encourage further declines toward 174.01. Intensifying bearish sentiment could then propel prices even lower, ultimately challenging today's bearish target of 172.28.
Meta Platforms Inc (META)
Meta is trading close to the significant pivot area of 689.09. Bulls need immediate action, first establishing firm control above 692.10, converting it into robust intraday support. This move could ignite bullish sentiment, targeting an advance toward 695.62, with sustained upward momentum potentially extending prices to 699.93. An extremely bullish scenario today could push Meta toward our upper daily target at 704.07.&nbsp;
Should Meta lose its footing at 689.09, bearish pressure would likely intensify, targeting the downside support level at 683.97. Continued selling would expose the next support zone at 679.79. A decisive breach here would invite aggressive bearish momentum, driving prices toward our lower daily bearish target at 676.46.
Tesla Inc. (TSLA)
Tesla is trading around the essential pivot point at 333.93. Bulls aim to quickly drive prices upward toward the resistance area at 340.97. Sustained buying strength here could encourage further bullish momentum, testing higher levels such as 346.64 and potentially reaching 350.87. Exceptional buying momentum could ultimately elevate Tesla prices toward today&#8217;s high bullish target at 356.80.&nbsp;
If Tesla cannot sustain the critical support at 333.93, bears are likely to aggressively target a downward push to 327.59. Further selling pressure could then bring the next support at 322.52 into play. A clear breakdown here would signal increased bearish momentum, driving prices toward our lower bearish target at 315.93.
Final Word:
Today&#8217;s trading session begins with the Empire Manufacturing report for June, providing early insights into industrial trends and economic sentiment. Following this, the market will closely monitor the Treasury's 3 and 6 Month Bill Auction at 11:30 AM ET, with heightened attention on the key 20-Year Bond Auction scheduled for 1 PM ET. These auctions often significantly impact market liquidity and can introduce notable volatility.&nbsp;
Given the limited economic data today, coupled with the expiration of numerous contracts during this roll week and the upcoming Federal Reserve&#8217;s FOMC meeting on Wednesday, expect pronounced market volatility. Traders should approach today&#8217;s session cautiously, keeping disciplined risk management at the forefront to navigate potential price swings.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks Today Using Technical Analysis

B of A Securities analyst Vivek Arya reinstates Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and announces $38 price target.

ALGM

B of A Securities Reinstates Buy on Allegro Microsystems, Announces $38 Price Target

B of A Securities analyst Brad Sills initiates coverage on Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Buy rating and announces Price Target of $42.

HNGE

B of A Securities Initiates Coverage On Hinge Health with Buy Rating, Announces Price Target of $42

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) may be gearing up for a rebound as strong technical signals and positive ecosystem <a href="https://www.benzinga.com/crypto">developments boost trader confidence</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1767</td>
<td>$26.5 billion</td>
<td>+1.4%&nbsp;</td>
<td>-4.9%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001214</td>
<td>$7.16 billion</td>
<td>+1.7%&nbsp;</td>
<td>-4.4%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001127</td>
<td>$4.7 billion</td>
<td>+1.2%&nbsp;</td>
<td>-5.9%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez reports that Dogecoin&#8217;s 12-hour chart has triggered multiple buy signals using the TD Sequential indicator, suggesting that selling pressure is easing and a near-term bounce could be imminent.
Key levels to watch include support at $0.22 and resistance at $0.25. A decisive break above the $0.25 level could open the door to higher price targets.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> prepares to rebound as the TD Sequential presents multiple buy signals on the 12-hour chart! <a href="https://t.co/ZTuoMyKROg">pic.twitter.com/ZTuoMyKROg</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1934570650896855218?ref_src=twsrc%5Etfw">June 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1934537195328766263">highlights</a> an &#8220;Adam and Eve&#8221; bottoming pattern forming on DOGE, which historically precedes bullish reversals.
Statistics: According to Coinglass, Dogecoin derivatives trading volume surged by 31.4%, with open interest ticking up 0.8% in the last 24 hours. Liquidations totalled $5.7 million, with $4.12 million coming from long positions.
In the options market, DOGE saw a massive 1,080.5% spike in trading volume and a 17.6% increase in open interest over the same period, indicating heightened trader interest.
Community News: Dogecoin's gaming sector is expanding, with PlaysOut <a href="https://www.panewslab.com/en/articles/ezflodf5">planning</a> to roll out 15 Dogecoin-themed mini games throughout 2025. The first game is scheduled for launch in August, playable via the MyDoge wallet and PlaysOut mobile app. These casual games will operate on the DogeOS application layer, further integrating DOGE into blockchain-based gaming.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45906017/dogecoin-drops-6-why-is-it-going-down">Dogecoin Drops 6%: Why Is It Going Down?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Gaming

$DOGE

$PEPE

$SHIB

DOGE

Dogecoin Flashes Multiple Buy Signals – Is A Rebound On The Horizon?

JMP Securities analyst Andrew Boone maintains Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) with a Market Outperform and raises the price target from $55 to $62.

JMP Securities Maintains Market Outperform on Life360, Raises Price Target to $62

Shares of electric vertical take-off and landing (eVTOL)&nbsp;company Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) are trading higher. The company on Monday announced a deal to launch its <a href="https://www.benzinga.com/pressreleases/25/06/b45942679/archer-announces-third-launch-edition-partner-striking-deal-to-deploy-midnight-aircraft-in-indones">Midnight aircraft in Indonesia</a>.
What Happened: Archer and PT. Industri Ketahanan Nasional (IKN)&nbsp;signed an agreement to deploy a fleet of Midnight aircraft in Indonesia under the company&#8217;s launch edition program. 
The agreement includes the planned purchase of up to 50 Midnight aircraft, valued at up to $250 million. In addition to launching the vehicles for air taxi services, the companies plan to explore other use cases centered around commercial and military logistics and environmental surveillance. 
&#8220;The level of demand for our ‘Launch Edition&#8217; program continues to grow. Indonesia represents a tremendous opportunity for our Midnight aircraft both in the near and long-term, with thousands of islands, a booming tourism sector and the development of a new capital city, Ibu Kota Nusantara,&#8221; said Adam Goldstein, founder and CEO of Archer.
PT. IKN is an Indonesian company focused on advancing national initiatives through government partnerships. The agreement makes Indonesia the third country Archer is planning to launch its Midnight aircraft in after announcing prior deals in the UAE and Ethiopia. 
Canaccord Genuity analyst Austin Moeller maintained Archer with a <a href="https://www.benzinga.com/analyst-stock-ratings">Buy</a> rating and lowered the price target from&nbsp;$13.50&nbsp;to&nbsp;$13 on Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45896929/trump-launches-aviation-overhaul-archer-joby-new-horizon-aerovironment-rally-as-us-targets-drone-evtol-supersonic-comeback">Trump Launches Aviation Overhaul: Archer, Joby, New Horizon, AeroVironment Rally As US Targets Drone, eVTOL, Supersonic Comeback</a>
<h3 class="wp-block-heading">How To Buy ACHR Stock</h3>
By now you're likely curious about how to participate in the market for Archer Aviation &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
ACHR Price Action: Archer Aviation has a 52-week high of $13.92 and a 52-week low of $2.82, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. <a href="http://benzinga.com/quote/achr">Archer shares</a> were up 4.2% at $10.41 at the time of publication Monday.
Photo: Shutterstock.

Contracts

Global

ACHR

Archer Aviation Stock Rises On Deal To Deploy Midnight Aircraft In Indonesia

Citigroup analyst Andrew Kaplowitz maintains Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and raises the price target from $98 to $130.

Citigroup Maintains Buy on Vertiv Holdings, Raises Price Target to $130

Baird analyst Rob Oliver maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Neutral and raises the price target from $410 to $425.

ADBE

Baird Maintains Neutral on Adobe, Raises Price Target to $425

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Small Cap

$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Comments

SpringWorks Therapeutics

SpringWorks Therapeutics (SWTX) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL